Patents Examined by Jessica H. Roark
  • Antigen-binding constructs targeting HER2
    Patent number: 11028182
    Abstract: Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ECD2 domain of HER2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ECD2 of HER2 (HER2 ECD2) with increased affinity compared to a wild-type 2C4 antibody. Such antigen-binding polypeptide constructs comprise one or more amino acid modifications in the framework region and/or CDRs compared to the amino acid sequence of a wild-type 2C4 antibody that increase affinity of the antigen-binding polypeptide construct for ECD2 by 2-fold or greater. The antigen-binding constructs can inhibit the growth of HER2-expressing breast cancer cells and gastric cancer cells. Antigen-binding constructs in biparatopic format are internalized in HER2-expressing cells.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: June 8, 2021
    Assignee: Zymeworks Inc.
    Inventors: Eric Escobar-Cabrera, Leonard G. Presta
  • Glycan-interacting compounds and methods of use
    Patent number: 11028181
    Abstract: The present invention provides glycan-interacting antibodies and methods for producing glycan-interacting antibodies useful in the treatment and prevention of human disease, including cancer. Such glycan-interacting antibodies include humanized antibodies, derivatives and fragments thereof as well as related compositions and kits. Methods of using glycan-interacting antibodies for treatment and diagnosis are included.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: June 8, 2021
    Assignee: Seagen Inc.
    Inventors: David A. Eavarone, Jillian M. Prendergast, Jeffrey Behrens
  • Nanobody dimers linked via C-terminally engineered cysteins
    Patent number: 11021544
    Abstract: The present invention relates to dimers comprising a first polypeptide and a second polypeptide, wherein each of said first and second polypeptide comprises at least one immunoglobulin single variable domain (ISVD) and a C-terminal extension comprising a cysteine moiety (preferably at the C-terminus), wherein said first polypeptide and said second polypeptide are covalently linked via a disulfide bond between the cysteine moiety of said first polypeptide and the cysteine moiety of said second polypeptide, in which the dimer outperformed the benchmark constructs, e.g. cognate multivalent and multispecific constructs, in various assays. The present invention provides methods for making the dimers of the invention.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: June 1, 2021
    Assignee: Ablynx N.V.
    Inventors: Carlo Boutton, Daniel Janssen, Peter Casteels, Peter Schotte, Francis Descamps
  • Anti-CTLA-4 antibodies and methods of use thereof
    Patent number: 11013802
    Abstract: The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: May 25, 2021
    Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
  • Anti-AP2 antibodies and antigen binding agents to treat metabolic disorders
    Patent number: 11014979
    Abstract: This invention is in the area of improved anti-aP2 antibodies and antigen binding agents, and compositions thereof, which target the lipid chaperone aP2/FABP4 (referred to as “aP2”) for use in treating disorders such as diabetes, obesity, cardiovascular disease, fatty liver disease, and/or cancer, among others. In one aspect, improved treatments for aP2 mediated disorders are disclosed in which serum aP2 is targeted and the biological activity of aP2 is neutralized or modulated using low-binding affinity aP2 monoclonal antibodies, providing lower fasting blood glucose levels, improved systemic glucose metabolism, increased systemic insulin sensitivity, reduced fat mass, reduced liver steatosis, reduced cardiovascular disease and/or a reduced risk of developing cardiovascular disease.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: May 25, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Gökhan S. Hotamisligil, Mehmet F. Burak, Feyza Engin, Scott B. Widenmaier, Elisabeth Helen Roberts, Adrian Richard Moore, Carl Brendan Doyle, Ralph Adams, Karine Jeannine Madeleine Hervé, Shauna Mhairi Wales, Kerry Louise Tyson, Karen Inouye
  • Antibodies
    Patent number: 11008399
    Abstract: The present invention relates to antibodies binding to 5T4, including bispecific antibodies binding to 5T4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
    Type: Grant
    Filed: October 22, 2020
    Date of Patent: May 18, 2021
    Assignee: GENMAB A/S
    Inventors: David Satijn, Esther C. W. Breij, Bart E. C. G. De Goeij, Kristel Kemper, Patrick Engelberts, Edward N. Van Den Brink, Rik Rademaker, Dennis Verzijl, Sjeng Horbach, Paul Parren
  • Cytotoxicity-inducing therapeutic agent
    Patent number: 11001643
    Abstract: Multi specific antigen-binding molecules maintaining excellent cellular cytotoxicity and high stability, which comprise a domain that contains an antibody variable region having glypican 3-binding activity and a domain that contains an antibody variable region having T-cell receptor complex-binding activity are provided. Since the provided molecules show a strong cytotoxicity against cells and tissues expressing glypican 3, it is possible to produce pharmaceutical compositions for treating or preventing various cancers.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: May 11, 2021
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Junichi Nezu, Atsushi Narita, Takahiro Ishiguro, Mika Sakurai, Hirotake Shiraiwa, Naoka Hironiwa, Tomoyuki Igawa, Yumiko Kawai
  • Chimeric antigen receptors with integrated controllable functions
    Patent number: 10988542
    Abstract: The present invention relates to the field of cell immunotherapy and more particularly to a new generation of chimeric antigen receptors (CAR), allowing the control of immune cells endowed with such CARs through the interaction with small molecules. More particularly, the present invention relates to chimeric antigen receptor which comprise in at least one ectodomain a molecular switch turning the antigen binding function of the receptor from an off to on state, and vice versa. The present invention thus provides more controlled and potentially safer engineered CAR endowed immune cells, such as T-lymphocytes.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: April 27, 2021
    Assignee: CELLECTIS
    Inventors: Alexandre Juillerat, Philippe Duchateau, Laurent Poirot
  • CD123 specific chimeric antigen receptors for cancer immunotherapy
    Patent number: 10988541
    Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a CD123 monoclonal antibody, conferring specific immunity against CD123 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia.
    Type: Grant
    Filed: March 19, 2018
    Date of Patent: April 27, 2021
    Assignee: CELLECTIS
    Inventor: Roman Galetto
  • Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
    Patent number: 10981997
    Abstract: Provided herein are antibodies that selectively bind to complex comprising a non-classical HLA-I (e.g. HLA-E) and a neoantigen having variable heavy chain domains (VH), variable light chain domains (VL), and complementarity determining regions (CDRs) as disclosed herein, as well as methods and uses thereof.
    Type: Grant
    Filed: July 10, 2020
    Date of Patent: April 20, 2021
    Assignee: ABEXXA BIOLOGICS, INC.
    Inventors: Jon Weidanz, Katherine Upchurch-Ange
  • Chimeric antigen receptors, and T cells in which chimeric antigen receptor is expressed
    Patent number: 10975148
    Abstract: Disclosed is a chimeric antigen receptor comprising an antigen binding domain; a hinge region; a transmembrane domain; a costimulatory domain; and a cytoplasmic signaling domain.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: April 13, 2021
    Assignee: CELLABMED INC.
    Inventor: Seogkyoung Kong
  • Antibody therapeutics that bind CD123
    Patent number: 10934361
    Abstract: There is disclosed compositions and methods relating to or derived from anti-CD123 antibodies. More specifically, there is disclosed fully human antibodies that bind CD123, CD123-antibody binding fragments and derivatives of such antibodies, and CD123-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: March 2, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: Heyue Zhou, John Dixon Gray
  • Bispecific antibody format
    Patent number: 10927185
    Abstract: [Problem] Provided is a bispecific antibody with a novel format that retains high binding affinity to both antigens, and can be efficiently produced in a commercial production process.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: February 23, 2021
    Assignee: Astellas Pharma Inc.
    Inventors: Yasuhiro Ito, Atsuo Yonezawa
  • Antibody therapeutics that bind TIM3
    Patent number: 10927171
    Abstract: There is disclosed compositions and methods relating to or derived from anti-TIM3 antibodies. More specifically, there is disclosed fully human antibodies that bind TIM3, TIM3-antibody binding fragments and derivatives of such antibodies, and TIM3-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: February 23, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventors: John Dixon Gray, Heyue Zhou, Irina Krapf
  • Antigen binding proteins that bind PD-L1
    Patent number: 10919964
    Abstract: There is disclosed anti-PD-L1 IgG class antibodies that have an improved ability to be manufactured at higher yields. More specifically, there is disclosed human antibodies that bind PD-L1, PD-L1-binding fragments that can be manufactured at higher yields.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: February 16, 2021
    Assignee: Sorrento Therapeutics, Inc.
    Inventor: Heyue Zhou
  • Antifibrotic activity of GAS6 inhibitor
    Patent number: 10876176
    Abstract: Compositions and methods are provided for treating fibrosis in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits AXL, MER or Tyro3 protein activity, for example by inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: December 29, 2020
    Assignees: Aravive Biologics, Inc., The Board of Trustees of the Leland Stanford Junior University
    Inventors: Raymond Tabibiazar, Amato J. Giaccia, Mihalis Kariolis, Yu Rebecca Miao
  • Chimeric receptors and methods of use thereof
    Patent number: 10875919
    Abstract: The present disclosure is related to compositions that include polynucleotides encoding chimeric receptors, methods of delivering polynucleotides encoding chimeric receptors to immune cells, and methods of using immune cells encoding chimeric receptors to treat or prevent cancer.
    Type: Grant
    Filed: April 26, 2017
    Date of Patent: December 29, 2020
    Assignee: ALECTOR LLC
    Inventor: Arnon Rosenthal
  • Combination of immunotherapy with local chemotherapy for the treatment of malignancies
    Patent number: 10864180
    Abstract: The presently disclosed subject matter provides methods, compositions, and kits for the treatment of cancer using a combination treatment comprising a locally administered chemotherapy and an immunotherapeutic agent. The presently disclosed subject matter also provides methods of promoting the combination treatment and instructing a patient to receive the combination treatment are also provided, as well immunotherapeutic, non-immunosuppressive compositions comprising the combination treatment, and methods of using the immunotherapeutic, non-immunosuppressive compositions for treating cancer.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: December 15, 2020
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Dimitrios Mathios, Betty Tyler, Drew Pardoll, Henry Brem, Michael Lim
  • Anti-PTK7 antibodies and methods of use
    Patent number: 10836831
    Abstract: Anti-PTK7 modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat hyperproliferative disorders are provided.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 17, 2020
    Assignee: ABBVIE STEMCENTRX LLC
    Inventors: Orit Foord, Scott J. Dylla, Robert A. Stull, Alex Bankovich, Alexandra Leida Liana Lazetic, Jeffrey Bernstein
  • Nucleic acid molecules encoding chimeric antigen receptors targeting B-cell maturation antigen and uses thereof
    Patent number: 10821135
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating multiple myeloma. It relates to chimeric antigen receptors (CARs) that specifically target B cell maturation antigen (BMCA), and immunoresponsive cells comprising such CARs. The presently disclosed BMCA-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Grant
    Filed: April 9, 2020
    Date of Patent: November 3, 2020
    Assignees: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Cheng Liu